Disodiumpyrophosphate ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
166 | 弾性線維性仮性黄色腫 | 2 |
166. 弾性線維性仮性黄色腫
臨床試験数 : 15 / 薬物数 : 27 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 28
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04441671 (ClinicalTrials.gov) | December 8, 2020 | 20/1/2020 | Oral Pyrophosphate Absorption in PXE Disease | Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE) | Pseudoxanthoma Elasticum | Drug: Disodium Pyrophosphate | Tampere University Hospital | UMC Utrecht;Hungarian Academy of Sciences | Withdrawn | 18 Years | 80 Years | All | 0 | Phase 2 | NULL |
2 | EUCTR2019-002109-24-FI (EUCTR) | 01/08/2019 | 01/07/2019 | Oral Pyrophosphate Absorption in PXE Disease | Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum - Oral Pyrophosphate Absorption in PXE | Pseudoxanthoma elasticum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Disodiumpyrophosphate | Tampere University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Finland |